• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CUI Tingting,YANG Yong.Progress in pharmacotherapy for the advanced hepatocellular carcinoma[J].Journal Of Pharmaceutical Research,2018,37(2):108-111[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3625times   Download 2827次 QR Code for this article
Scan with your phone!
晚期原发性肝癌药物治疗研究进展
崔婷婷,杨勇
Font:Larger+|Default|Smaller-
(中国药科大学药物科学研究院,江苏 南京 211198)
摘要:
肝癌是临床常见的恶性肿瘤之一,在全球最常见恶性肿瘤中居第六位,在肿瘤相关致死率中占第三位。由于多数肝癌患者确诊时已是晚期,且对于晚期原发性肝癌缺乏有效的治疗措施,肝癌的治疗仍然是临床一大难题。临床上放射性治疗和肝移植手术等只对早期肝癌有效,对于晚期原发性肝癌的治疗多采用全身系统性治疗,主要包括分子靶向药物治疗,化疗等,其中索拉非尼是晚期肝癌药物治疗的金标准。本文对晚期原发性肝癌药物治疗最新进展作一综述
关键词:  晚期原发性肝癌  分子靶向治疗化疗  药物治疗
DOI:10.13506/j.cnki.jpr.2018.02.012
基金项目:
Progress in pharmacotherapy for the advanced hepatocellular carcinoma
CUI Tingting,YANG Yong
(Institute of Pharmaceutical Science,China Pharmaceutical University,Nanjing 211198,China)
Abstract:
Hepatocellular carcinoma (HCC) is the sixth common primary tumor.and the third cause of cancer-related death worldwide.Despite the spread of HCC,its treatment is still a hard challenge, due to high rate of late diagnosis and to lack of therapeutic options for advanced disease. In fact radical surgery and liver transplantation, the most radical therapeutic approaches, are indicated only in case of early diagnosis.Systemic therapy is particularly important for patients with advanced HCC,including targeted agent therapy and chemotherapy,with sorafenib as the only standard treatment available.In this review,we discussed the current situation and progress of systemic therapies for the advanced HCC.
Key words:  Hepatocellular carcinoma  Targeted agent therapy chemotherapy  Pharmacotherapy
Today's Visits:464    Total Visits:2383159
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.